Table 3 Demographic characteristics and mean weight and IgE of patients in the included studies
From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
Study ID | Interventions | Age (mean ± SD) | Female sex n(%) | Caucasian n(%) | Weight (kg) mean ± SD | <80 kg n (%) | IgE (IU/mL) mean ± SD | IgE (IU/mL) median (range) |
|---|---|---|---|---|---|---|---|---|
1 | Omalizumab 75-375 | 39.1 ± 9.0 | 19 (70.4) | 27 (100.0) | 81.9 ± 20.2 | - | 211 ± 158 | - |
Placebo | 42.3 ± 15.0 | 19 (86.4) | 22 (100.0) | 71.2 ± 12.4 | - | 181 ± 136 | - | |
2 | Omalizumab 75 | 38.8 ± 15.5 | 15 (65.2) | 20 (87.0) | 80.5 ± 21.6 | 14 (60.9) | 251.5 ± 389.6 | 62 (3–1500) |
Omalizumab 300 | 42.9 ± 15.7 | 17 (68.0) | 19 (76.0) | 82.2 ± 22.8 | 13 (52.0) | 170.5 ± 178.5 | 131.5 (2–819) | |
Omalizumab 600 | 40 ± 11.1 | 12 (57.1) | 18 (85.7) | 80.6 ± 18.1 | 11 (52.4) | 134.9 ± 142.9 | 90 (4–617) | |
Placebo | 41.2 ± 16.2 | 17 (81) | 18 (85.7) | 80.4 ± 24.8 | 13 (61.9) | 297.4 ± 748.9 | 62 (3–1500) | |
3 | Omalizumab 75 | 39.7 ± 15.0 | 61 (74.0) | 64 (78.0) | 82.8 ± 21.2 | 43 (52.4) | 168.2 ± 321.9** | 79 |
Omalizumab 150 | 43.0 ± 13.2 | 65 (79.0) | 70 (85.0) | 82.4 ± 20.7 | 41 (49.4) | - | - | |
Omalizumab 300 | 44.3 ± 13.7 | 63 (80.0) | 68 (86.0) | 80.3 ± 19.9 | 41 (51.9) | - | - | |
Placebo | 43.1 ± 12.5 | 55 (70.0) | 70 (89. 0) | 84.3 ± 25.7 | 41 (51.9) | - | - | |
4 | Omalizumab 300 | 42.7 ± 17.9 | 186 (73.8) | 223 (88.5) | 29.4 ± 7.1* | - | 162.3 ± 306.4 | 79 (1–3050) |
Placebo | 44.3 ± 14.7 | 55 (66.3) | 75 (90.4) | 31 ± 9.6* | - | 147.2 ± 224.4 | 71 (1–1230) | |
5 | Omalizumab 75 | 40.7 ± 15.2 | 55 (71.4) | 62 (80.5) | 81.1 ± 19.2 | 38 (48.7) | - | 91 (1–2030) |
Omalizumab 150 | 41.1 ± 14 | 64 (80.0) | 63 (78.8) | 83.2 ± 24.4 | 40 (50.0) | - | 71 (1–5000) | |
Omalizumab 300 | 42.4 ± 13.2 | 60 (74.1) | 74 (91.4) | 81.6 ± 19.7 | 45 (55.5) | - | 85.5 (1–2330) | |
Placebo | 40.4 ± 15.6 | 52 (65.0) | 64 (80.0) | 83 ± 20.5 | 35 (43.7) | - | 92 (1–1010) |